Clarivate Epidemiology's coverage of Pemphigus vulgaris comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Pemphigus vulgaris for each country as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology's Pemphigus vulgaris forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of dyslipidemai?
In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of Pemphigus vulgaris?
Of all people diagnosed with Pemphigus vulgaris, how many in each country across the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of Pemphigus vulgaris over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Utsav Patel, M.P.H.,is an associate epidemiologist at Clarivate. His areas of interest are cardiovascular diseases and cancer epidemiology. Previously, he worked as a graduate research assistant at City University of New York, where he conducted multi-omics investigations into cancer study funded by the National Institutes of Health. He obtained his M.P.H. in epidemiology and biostatistics from City University of New York.
T.J. Arndt, M.P.H., C.P.H.
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.